Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.

Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM.

Lancet. 2009 Jan 3;373(9657):31-41. doi: 10.1016/S0140-6736(08)61764-X. Epub 2008 Dec 6.

PMID:
19058842
2.

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.

Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM.

Lancet. 2013 Sep 14;382(9896):951-62. doi: 10.1016/S0140-6736(13)60733-3. Epub 2013 Jun 27. Review. Erratum in: Lancet. 2013 Sep 14;382(9896):940.

PMID:
23810019
3.

Haloperidol versus low-potency first-generation antipsychotic drugs for schizophrenia.

Tardy M, Huhn M, Kissling W, Engel RR, Leucht S.

Cochrane Database Syst Rev. 2014 Jul 9;(7):CD009268. doi: 10.1002/14651858.CD009268.pub2. Review.

PMID:
25007358
4.

Sertindole for schizophrenia.

Lewis R, Bagnall AM, Leitner M.

Cochrane Database Syst Rev. 2005 Jul 20;(3):CD001715. Review.

PMID:
16034864
5.

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis.

Leucht S, Wahlbeck K, Hamann J, Kissling W.

Lancet. 2003 May 10;361(9369):1581-9. Review.

PMID:
12747876
6.

Amisulpride for schizophrenia.

Mota NE, Lima MS, Soares BG.

Cochrane Database Syst Rev. 2002;(2):CD001357. Review.

PMID:
12076408
7.

Aripiprazole versus other atypical antipsychotics for schizophrenia.

Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, Leucht S, Xia J.

Cochrane Database Syst Rev. 2014 Jan 2;(1):CD006569. doi: 10.1002/14651858.CD006569.pub5. Review.

PMID:
24385408
8.

World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia.

Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker WW, Moeller HJ; Section of Pharmacopsychiatry, World Psychiatric Association.

Schizophr Res. 2008 Mar;100(1-3):20-38. doi: 10.1016/j.schres.2007.11.033. Epub 2008 Feb 19. Review.

PMID:
18243663
9.

Risperidone versus typical antipsychotic medication for schizophrenia.

Hunter RH, Joy CB, Kennedy E, Gilbody SM, Song F.

Cochrane Database Syst Rev. 2003;(2):CD000440. Review.

PMID:
12804396
10.

Zotepine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006628. doi: 10.1002/14651858.CD006628.pub2. Review. Update in: Cochrane Database Syst Rev. 2010;(10):CD006628.

PMID:
20091601
11.

Are second generation antipsychotics a distinct class?

Bonham C, Abbott C.

J Psychiatr Pract. 2008 Jul;14(4):225-31. doi: 10.1097/01.pra.0000327312.04153.da. Review.

12.

Perphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.

Tardy M, Huhn M, Engel RR, Leucht S.

Cochrane Database Syst Rev. 2014 Oct 7;(10):CD009369. doi: 10.1002/14651858.CD009369.pub2. Review.

PMID:
25290157
13.

Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophrenia.

Tardy M, Huhn M, Engel RR, Leucht S.

Cochrane Database Syst Rev. 2014 Aug 3;(8):CD009230. doi: 10.1002/14651858.CD009230.pub2. Review.

PMID:
25087165
14.

A review and Bayesian meta-analysis of clinical efficacy and adverse effects of 4 atypical neuroleptic drugs compared with haloperidol and placebo.

Klemp M, Tvete IF, Skomedal T, Gaasemyr J, Natvig B, Aursnes I.

J Clin Psychopharmacol. 2011 Dec;31(6):698-704. doi: 10.1097/JCP.0b013e31823657d9. Review.

PMID:
22020356
15.

Perazine for schizophrenia.

Leucht S, Helfer B, Hartung B.

Cochrane Database Syst Rev. 2014 Jan 15;(1):CD002832. doi: 10.1002/14651858.CD002832.pub3. Review.

PMID:
24425538
16.

Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia.

Tardy M, Dold M, Engel RR, Leucht S.

Cochrane Database Syst Rev. 2014 Jul 8;(7):CD009396. doi: 10.1002/14651858.CD009396.pub2. Review.

PMID:
25003310
17.

Pimozide for schizophrenia or related psychoses.

Mothi M, Sampson S.

Cochrane Database Syst Rev. 2013 Nov 5;(11):CD001949. doi: 10.1002/14651858.CD001949.pub3. Review.

PMID:
24194433
18.

Risperidone versus typical antipsychotic medication for schizophrenia.

Kennedy E, Song F, Hunter R, Clarke A, Gilbody S.

Cochrane Database Syst Rev. 2000;(2):CD000440. Review. Update in: Cochrane Database Syst Rev. 2003;(2):CD000440.

PMID:
10796543
19.

Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons.

Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Kissling W, Davis JM, Leucht S.

Schizophr Bull. 2012 Jan;38(1):167-77. doi: 10.1093/schbul/sbq042. Epub 2010 May 31. Review.

20.

Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophrenia.

Tardy M, Dold M, Engel RR, Leucht S.

Cochrane Database Syst Rev. 2014 Sep 1;(9):CD009227. doi: 10.1002/14651858.CD009227.pub2. Review.

PMID:
25177834

Supplemental Content

Support Center